And, as he showed today at Fortune's Brainstorm Tech Conference in Aspen, the dude is eminently quotable no matter the subject — success or failure.
9.49am: Some news from my colleague Jess Shepherd about the breakdown of subject successes, with maths and science having a good year.
For Lacy's other subjects, repeated success has yet to be determined.
What mattered, it turned out, was not whether the subjects achieved success but what they had to endure to get there.
Both the Rivers and Sassoon films illustrate that their subjects' sustained success is no accident: both are driven by a relentless, controlling perfectionism and workaholic personalities.
The implications of the calculations will have far-reaching effects on the feasibility of the study such as availability of subjects, the success with recruitment, and the overall expenses.
In short, we applied the standard quality control pipeline for subjects (genotype success rate >95%, genotype-derived gender concordant with reported gender, excess inter/intra-heterozygosity) and for SNPs (Hardy-Weinberg Equilibrium p>1×10−6; Minor Allele Frequency >0.01, genotype call rate >0.95).
In two additional subjects, partial success was achieved (not all planned sinuses were successfully dilated).
In non-ICU subjects, treatment success was significantly higher for micafungin versus liposomal amphotericin B (85% (n = 108/127) versus 72.1% (n = 98/136); P = 0.0113).
However, for ICU subjects, treatment success rates for micafungin versus liposomal amphotericin B were similar (62.5% (n = 75/120) versus 66.4% (n = 73/110); P = 0.5828).
